AstraZeneca PLC is transferring the listing of its American depositary receipts and its U.S.-listed debt securities to the Nasdaq Global Select Market and Nasdaq Bond Exchange, respectively.

The ADRs and debt securities are currently listed on the New York Stock Exchange.

The transfers will take effect after market close Sept. 24, with the ADRs and debt securities anticipated to begin trading on Nasdaq the following day. The ADRs will retain the AZN ticker, the company said in a Sept. 10 news release.

Cambridge, U.K.-based AstraZeneca, the largest British pharmaceutical company, said its primary listing on the London Stock Exchange and on Nasdaq Stockholm are unaffected by the U.S. changes.

AstraZeneca CFO Marc Dunoyer said the stock exchange move is intended to cut the overall listing cost of the company's equity and debt securities.